All In Biotech

Drug Trial Radar · NCT04525729

Rituximab and RASi in Patients with IgAN

A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Jul 1, 2020

Primary completion

Mar 30, 2024

Study completion Mar 30, 2024

Sponsor

Lead sponsor
Nan Chen,MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dongfang Hospital Affiliated to Tongji University; Shanghai Pudong New Area People's Hospital; Ruijin Hospital; Ningbo Municipal Yinzhou District No.2 Hospital; Third Affiliated Hospital, Sun Yat-Sen University; Xiamen Hong'ai Hospital; Sir Run Run Shaw Hospital; Tongji Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First posted
Aug 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

Conditions

  • IgA Nephropathy

Interventions

  • RituximabDrug

    To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.

  • RAS 2410Drug

    To evaluate the efficacy and safety of RASi in patients with IgAN.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in proteinuria levels over 1 year compared with baselineTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.